Swallowing, nutritional status, and markers of inflammation and oxidative stress in a Children's Hospital.

Not Applicable

Completed

• Conditions: Cystic fibrosis; Human Genetics and Inherited Disorders - Cystic fibrosis; Diet and Nutrition - Other diet and nutrition disorders; Inflammatory and Immune System - Other inflammatory or immune system disorders

• Registration Number: ACTRN12611001217998
• Lead Sponsor: Emilia Addison Machado Moreira

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-11-25
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

Experimental group: children and adolescents diagnosed with cystic fibrosis with impairment classified as moderate score of Schwachman-Kulczicki. Clinically stable for at least thirty days prior to data collection.
Control group: children and adolescents without cystic fibrosis and without inflammatory symptoms, normal for weight, and paired in age and sex with the cystic fibrosis group.

Exclusion Criteria

Experimental group: patients on antibiotics during or even a month before the day of collection and those in period of pulmonary exacerbation. Individuals undergoing mechanical ventilation, intubated-tracheotomised (up to 3 months before or at the time of assessment), undergoing nutritional-enteral therapy, or suffering from cerebral palsy, autism, encephalopathy, Down’s syndrome and other conditions that would compromise swallowing, in a terminal stage. Individual suffering from inflammatory (asthma, intestinal inflammatory illness, rheumatic illness), neurological or degenerative illnesses, renal insufficiency and/or diabetes mellitus, or using antibiotics and/or hormones or non-hormonal anti-inflammatory drugs, up to 6 months before the study.
Control group: Individuals suffering from inflammatory (asthma, intestinal inflammatory illness, rheumatic illness), neurological or degenerative illnesses, renal insufficiency and/or diabetes mellitus, or using antibiotics and/or hormones or non-hormonal anti-inflammatory drugs, up to 6 months before the study. Individuals with symptoms of gastroesophageal reflux (heartburn, regurgitation of food, frequent cough).

Study & Design

• Study Type: Observational
• Study Design: Not specified